|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objectives of this study were to investigate in colonic mucosa the effects of a high-fat diet rich in LA (<i>n</i>-6HFD) on CpG methylation of <i>Fxr</i> and prostaglandin-endoperoxide synthase-2 (<i>Ptsg-2</i>) genes, and the impact on the expression of tumor suppressor adenomatous polyposis Coli (<i>Apc</i>) and proliferative cyclin D1 (<i>Ccnd1</i>) genes.
|
30650553 |
2019 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the Apc<sup>Min/+</sup> model of familial adenomatous polyposis (MMR-proficient CRC), increased Cyclooxygenase-2 (Cox-2) expression by cells which include alternatively activated mononuclear phagocytes promotes intestinal tumorigenesis by mechanisms which may include immune suppression.
|
28940183 |
2018 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, 6G significantly inhibited nuclear factor kappa B (P65), p38, cyclooxygenase-2, and β-catenin whereas it enhanced IL-10 and adenomatous polyposis coli expression in DSS-treated mice.
|
29350052 |
2018 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We conclude that the loss of APC function favors the silencing of FXR expression through CpG hypermethylation in mouse colonic mucosa and human colon cells, leading to reduced expression of downstream targets (SHP, IBABP) involved in BA homeostasis while increasing the expression of factors (COX-2, c-MYC) that contribute to inflammation and colon cancer.
|
26609171 |
2016 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COX-2 mRNA levels in normal duodenal mucosa of patients with FAP were found to be unexpectedly low.
|
24245549 |
2013 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Selective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP.
|
20593240 |
2010 |
|
Adenomatous Polyposis Coli
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients having either APC missense mutations or b-catenin nuclear accumulation had less frequent COX-2 overexpression (24% vs. 76%, p = 0.043) and more frequent lymph node involvement (75% vs. 38%, p = 0.023).
|
18844223 |
2009 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclooxygenase-2 (COX-2) expression is increased in gastrointestinal tumorigenesis and familial adenomatous polyposis.
|
19124115 |
2009 |
|
Adenomatous Polyposis Coli
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The predicted low COX-2 expression genotype -1195GG was found overrepresented in the patients with FAP.
|
19544971 |
2009 |
|
Adenomatous Polyposis Coli
|
0.400 |
Biomarker
|
disease |
BEFREE |
Positive cytoplasmic HuR immunostaining correlated with high COX-2 immunoreactivity in colon mucosa of FAP patients (p < 0.01) and in sporadic colorectal carcinomas.(p = 0.016)
|
18094611 |
2008 |
|
Adenomatous Polyposis Coli
|
0.400 |
Biomarker
|
disease |
CTD_human |
Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse.
|
17942926 |
2007 |
|
Adenomatous Polyposis Coli
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tumor specimens from 14 patients surgically treated for aggressive fibromatosis (6 familial adenomatous polyposis and 8 sporadic cases), analyzed for adenomatous polyposis coli (APC) and CTNNB1 (beta-catenin) mutations, were further investigated for beta-catenin, cyclooxygenase-2 (COX-2), platelet-derived growth factor (PDGF) receptor alpha (PDGFRA)/PDGF receptor beta (PDGFRB), their cognate ligands (PDGFA and PDGFB), and KIT using a comprehensive immunohistochemical, biochemical, molecular, and cytogenetic approach.
|
17785554 |
2007 |
|
Adenomatous Polyposis Coli
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatments with COX-2-specific NSAIDs have been shown to reduce polyp size and polyp number in FAP patients with a predisposition to colorectal adenoma and cancer.
|
16391811 |
2006 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Cyclooxygenase-2 expression in the hereditary mixed polyposis syndrome.
|
15628724 |
2005 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, patients with MYH mutations showed a weak COX-2 expression in the whole colorectal mucosa, as for classic FAP patients carrying germ line APC mutations.
|
16103460 |
2005 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, the normal duodenum of patients with FAP showed higher COX-2 expression than the normal duodenal mucosa of patients with sporadic adenomas (P < 0.05).
|
15930344 |
2005 |
|
Adenomatous Polyposis Coli
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, treatment with COX-2-selective inhibitors reduces polyp burden in animal models of intestinal neoplasia and in humans with familial adenomatous polyposis (FAP).
|
15285921 |
2004 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Effects on NF kappa B and apoptosis were observed irrespective of COX-2 expression, or mutation status in APC, beta-catenin, p53 and DNA MMR genes, underscoring the generality of the aspirin effect on NF kappa B in CRC cells.
|
15188000 |
2004 |
|
Adenomatous Polyposis Coli
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The clinical use of these agents is limited to patients with familial adenomatous polyposis (FAP), which may benefit from chemopreventive treatment with sulindac or the selective COX-2 inhibitor celecoxib.
|
14508092 |
2004 |
|
Adenomatous Polyposis Coli
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study was designed to determine whether: (a) chronic administration of dietary celecoxib (Celebrex), a potent nonsteroidal anti-inflammatory drug, which targets the cyclooxygenase-2 (COX-2) enzyme, negatively impacts host immunity; and (b) celecoxib can be coupled with a poxvirus-based vaccine to impact tumor burden in a murine tumor model of spontaneous adenomatous polyposis coli.
|
15150127 |
2004 |
|
Adenomatous Polyposis Coli
|
0.400 |
Biomarker
|
disease |
BEFREE |
Specifically, chemoprevention trials are currently ongoing to evaluate the efficacy of COX-2 inhibitors in the prevention of colorectal cancer in HNPCC and familial adenomatous polyposis patients.
|
14585257 |
2003 |
|
Adenomatous Polyposis Coli
|
0.400 |
Biomarker
|
disease |
BEFREE |
A new class of non-steroidal anti-inflammatory drugs (NSAIDs), the specific cyclooxygenase 2 (COX-2) inhibitors, have recently been applied for the treatment of FAP patients.
|
12174906 |
2002 |
|
Adenomatous Polyposis Coli
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Over the past decade, in vitro, preclinical, and clinical data have supported the hypothesis that cyclooxygenase (COX)-2 plays a central role in oncogenesis and that treatment with COX-2 inhibitors offers an effective chemoprevention strategy, as exemplified by the activity of celecoxib (Celebrex) in familial adenomatous polyposis.
|
12102579 |
2002 |
|
Adenomatous Polyposis Coli
|
0.400 |
Biomarker
|
disease |
BEFREE |
A genetic study using compound mutant mice of COX-2(-)/(-), and Apc(Delta716) which is a model for human familial adenomatous polyposis (FAP), directly demonstrated that induction of COX-2 is critical for intestinal polyp formation.
|
11945149 |
2002 |
|
Adenomatous Polyposis Coli
|
0.400 |
Biomarker
|
disease |
BEFREE |
An identified putative Tcf-4 binding element in the COX-2 promoter may partly explain the enhanced level of COX-2 and support the idea that COX-2 may be a downstream target of the APC/beta-catenin/Tcf-4 pathway.
|
11396184 |
2001 |